Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVER001 in Primary Membranous Nephropathy
NCT05800873Phase 1Completed
- Sponsor
- Everest Medicines
- Start
- May 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ever001 in primary membranous nephropathy (PMN) (2 arms), sponsored by Everest Medicines. Primary endpoints: Adverse Events at 104 weeks, Clinical Laboratory Assessments at 104 weeks and 3 more. Started May 2023; status: completed.
02
Drugs
ever001
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05800873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800873.